Genmab (GMAB) Stock Forecast, Price Target & Predictions
GMAB Stock Forecast
Genmab stock forecast is as follows: an average price target of $43.00 (represents a 56.25% upside from GMAB’s last price of $27.52) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
GMAB Price Target
The average price target for Genmab (GMAB) is $43.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $53.00 to $31.00. This represents a potential 56.25% upside from GMAB's last price of $27.52.
GMAB Analyst Ratings
According to 9 Wall Street analysts, Genmab's rating consensus is 'Buy'. The analyst rating breakdown for GMAB stock is 0 'Strong Buy' (0.00%), 6 'Buy' (66.67%), 3 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Genmab Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Vikram Purohit | Morgan Stanley | $31.00 | $27.41 | 13.10% | 12.65% |
| Aug 09, 2024 | Etzer Darout | BMO Capital | $46.00 | $27.07 | 69.93% | 67.15% |
| Jun 27, 2024 | Kaveri Pohlman | BTIG | $47.00 | $25.67 | 83.09% | 70.78% |
| Jun 27, 2024 | Raghuram Selvaraju | H.C. Wainwright | $50.00 | $25.71 | 94.48% | 81.69% |
| Jun 04, 2024 | Asthika Goonewardene | Truist Financial | $53.00 | $28.83 | 83.84% | 92.59% |
| Feb 23, 2024 | Etzer Darout | BMO Capital | $48.00 | $29.16 | 64.61% | 74.42% |
| Feb 06, 2023 | - | Leerink Partners | $36.00 | $38.26 | -5.91% | 30.81% |
| Nov 28, 2022 | Matthew Harrison | Morgan Stanley | $34.00 | $44.83 | -24.16% | 23.55% |
| May 02, 2022 | - | Cowen & Co. | $38.00 | $34.91 | 8.85% | 38.08% |
The latest Genmab stock forecast, released on Sep 04, 2024 by Vikram Purohit from Morgan Stanley, set a price target of $31.00, which represents a 13.10% increase from the stock price at the time of the forecast ($27.41), and a 12.65% increase from GMAB last price ($27.52).
Genmab Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 4 | 6 |
| Avg Price Target | $38.50 | $43.50 | $45.83 |
| Last Closing Price | $27.52 | $27.52 | $27.52 |
| Upside/Downside | 39.90% | 58.07% | 66.53% |
In the current month, the average price target of Genmab stock is $38.50, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 39.90% increase as opposed to Genmab's last price of $27.52. This month's average price target is down -11.49% compared to last quarter, and down -15.99% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Aug 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 01, 2024 | BTIG | Underperform | Underperform | Hold |
| Jul 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 15, 2024 | RBC Capital | - | Outperform | Upgrade |
| Jul 10, 2024 | Barclays | Overweight | Overweight | Hold |
| Jun 27, 2024 | BTIG | Buy | Buy | Hold |
| Jun 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | Truist Financial | Buy | Buy | Hold |
Genmab's last stock rating was published by H.C. Wainwright on Aug 20, 2024. The company gave GMAB a "Buy" rating, the same as its previous rate.
Genmab Financial Forecast
Genmab Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.85B | $5.23B | $4.09B | $3.16B | $2.12B | $2.62B | $2.31B | $1.97B | $1.58B | $2.04B | $1.72B | $5.45B | $892.00M | $2.96B | $1.04B |
| Avg Forecast | $8.31B | $8.04B | $7.83B | $6.65B | $6.90B | $6.53B | $5.74B | $5.33B | $5.85B | $5.67B | $5.08B | $3.97B | $4.55B | $4.55B | $4.10B | $2.77B | $4.71B | $3.61B | $2.93B | $300.49M | $389.00M | $339.46M | $270.57M | $220.61M | $292.26M | $237.70M | $864.17M | $131.08M | $397.13M | $136.73M |
| High Forecast | $8.96B | $8.67B | $8.45B | $7.17B | $7.44B | $7.04B | $6.19B | $5.75B | $6.31B | $6.13B | $5.48B | $4.28B | $4.78B | $5.03B | $4.43B | $2.99B | $5.08B | $3.89B | $2.93B | $327.31M | $423.73M | $369.76M | $294.72M | $240.30M | $318.35M | $258.91M | $941.31M | $142.79M | $432.58M | $148.93M |
| Low Forecast | $7.66B | $7.41B | $7.22B | $6.13B | $6.36B | $6.01B | $5.29B | $4.91B | $5.40B | $5.04B | $4.68B | $3.66B | $4.27B | $4.34B | $3.78B | $2.55B | $4.34B | $3.32B | $2.93B | $281.79M | $364.79M | $318.33M | $253.73M | $206.88M | $274.07M | $222.90M | $810.39M | $122.93M | $372.42M | $128.22M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.11% | 1.13% | 1.08% | 7.05% | 6.73% | 6.80% | 7.29% | 7.17% | 6.99% | 7.25% | 6.31% | 6.80% | 7.46% | 7.61% |
Genmab's average Quarter revenue forecast for Jun 23 based on 6 analysts is $4.10B, with a low forecast of $3.78B, and a high forecast of $4.43B. GMAB's average Quarter revenue forecast represents a 43.82% increase compared to the company's last Quarter revenue of $2.85B (Mar 23).
Genmab EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $629.00M | $2.81B | $2.03B | $2.69B | $550.00M | $969.00M | $1.40B | $852.00M | $1.43B | $-128.00M | $1.39B | $4.55B | $356.00M | $1.96B | $699.28M |
| Avg Forecast | $4.06B | $3.93B | $3.83B | $3.25B | $3.37B | $3.19B | $2.80B | $2.60B | $2.86B | $2.77B | $2.48B | $1.94B | $2.22B | $2.22B | $2.00B | $1.35B | $2.30B | $1.76B | $1.43B | $146.74M | $189.97M | $165.77M | $132.13M | $107.74M | $-216.62M | $116.08M | $422.02M | $64.01M | $193.94M | $66.77M |
| High Forecast | $4.38B | $4.23B | $4.13B | $3.50B | $3.63B | $3.44B | $3.02B | $2.81B | $3.08B | $3.00B | $2.68B | $2.09B | $2.34B | $2.46B | $2.16B | $1.46B | $2.48B | $1.90B | $1.43B | $159.84M | $206.93M | $180.57M | $143.93M | $117.35M | $-173.29M | $126.44M | $459.69M | $69.73M | $211.25M | $72.73M |
| Low Forecast | $3.74B | $3.62B | $3.53B | $2.99B | $3.11B | $2.94B | $2.59B | $2.40B | $2.64B | $2.46B | $2.29B | $1.79B | $2.08B | $2.12B | $1.85B | $1.25B | $2.12B | $1.62B | $1.43B | $137.61M | $178.15M | $155.46M | $123.91M | $101.03M | $-259.94M | $108.85M | $395.75M | $60.03M | $181.87M | $62.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.47% | 1.22% | 1.15% | 1.88% | 3.75% | 5.10% | 8.45% | 6.45% | 13.25% | 0.59% | 11.98% | 10.77% | 5.56% | 10.12% | 10.47% |
6 analysts predict GMAB's average Quarter EBITDA for Jun 23 to be $2.00B, with a high of $2.16B and a low of $1.85B. This is 218.68% upper than Genmab's previous annual EBITDA (Mar 23) of $629.00M.
Genmab Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $226.00M | $584.00M | $2.58B | $1.89B | $465.00M | $716.00M | $890.00M | $306.00M | $1.10B | $581.00M | $530.00M | $3.38B | $269.00M | $1.47B | $537.05M |
| Avg Forecast | $340.95M | $306.35M | $282.98M | $199.57M | $190.72M | $173.72M | $125.09M | $104.56M | $122.47M | $140.36M | $140.10M | $6.61B | $137.79M | $151.08M | $128.40M | $5.93B | $151.51M | $4.33B | $90.64M | $786.41M | $495.69M | $607.98M | $306.00M | $905.39M | $983.23M | $891.36M | $2.77B | $259.72M | $1.48B | $684.73M |
| High Forecast | $375.64M | $337.52M | $311.78M | $219.88M | $210.13M | $191.40M | $137.82M | $115.20M | $134.93M | $163.76M | $154.35M | $7.93B | $210.75M | $188.21M | $141.47M | $7.11B | $166.93M | $5.19B | $90.64M | $943.69M | $594.83M | $729.58M | $367.20M | $1.09B | $1.18B | $1.07B | $3.33B | $311.67M | $1.78B | $821.68M |
| Low Forecast | $306.27M | $275.18M | $254.19M | $179.27M | $171.32M | $156.05M | $112.37M | $93.93M | $110.01M | $116.97M | $125.85M | $5.29B | $85.11M | $133.78M | $115.34M | $4.74B | $136.10M | $3.46B | $90.64M | $629.13M | $396.55M | $486.39M | $244.80M | $724.31M | $786.58M | $713.09M | $2.22B | $207.78M | $1.18B | $547.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.04% | 3.85% | 0.60% | 20.86% | 0.59% | 1.44% | 1.46% | 1.00% | 1.21% | 0.59% | 0.59% | 1.22% | 1.04% | 0.99% | 0.78% |
Genmab's average Quarter net income forecast for Jun 23 is $128.40M, with a range of $115.34M to $141.47M. GMAB's average Quarter net income forecast represents a -43.19% decrease compared to the company's last Quarter net income of $226.00M (Mar 23).
Genmab SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $676.00M | $921.00M | $670.00M | $633.00M | $452.00M | $512.00M | $306.00M | $264.00M | $201.00M | $231.00M | $145.00M | $179.00M | $106.00M | $116.55M | $81.22M |
| Avg Forecast | $1.09B | $1.05B | $1.03B | $872.19M | $905.01M | $855.89M | $753.35M | $698.95M | $767.92M | $743.82M | $666.43M | $520.93M | $596.61M | $596.40M | $538.41M | $363.24M | $617.94M | $1.49B | $384.28M | $39.41M | $354.46M | $209.04M | $264.00M | $166.04M | $38.33M | $31.18M | $146.99M | $102.34M | $117.23M | $103.56M |
| High Forecast | $1.18B | $1.14B | $1.11B | $940.46M | $975.86M | $922.89M | $812.32M | $753.66M | $828.03M | $804.71M | $718.60M | $561.71M | $627.63M | $659.63M | $580.55M | $391.68M | $666.31M | $1.79B | $384.28M | $42.93M | $425.35M | $250.84M | $316.80M | $199.25M | $41.76M | $33.96M | $176.38M | $122.81M | $140.68M | $124.27M |
| Low Forecast | $1.00B | $971.90M | $947.15M | $803.94M | $834.20M | $788.92M | $694.40M | $644.26M | $707.83M | $661.33M | $614.28M | $480.17M | $559.91M | $569.03M | $496.28M | $334.82M | $569.59M | $1.19B | $384.28M | $36.96M | $283.57M | $167.23M | $211.20M | $132.83M | $35.95M | $29.24M | $117.59M | $81.88M | $93.78M | $82.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.86% | 1.49% | 0.45% | 1.65% | 11.47% | 1.44% | 1.46% | 1.00% | 1.21% | 6.03% | 4.65% | 1.22% | 1.04% | 0.99% | 0.78% |
Genmab's average Quarter SG&A projection for Jun 23 is $538.41M, based on 6 Wall Street analysts, with a range of $496.28M to $580.55M. The forecast indicates a -20.35% fall compared to GMAB last annual SG&A of $676.00M (Mar 23).
Genmab EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 9 | 6 | 4 | 3 | 7 | 5 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.35 | $0.89 | $3.96 | $2.89 | $0.71 | $1.09 | $1.36 | $0.47 | $1.68 | $0.89 | $0.81 | $5.19 | $0.41 | $2.30 | $0.84 |
| Avg Forecast | $5.25 | $4.72 | $4.36 | $3.08 | $2.94 | $2.68 | $1.93 | $1.61 | $1.89 | $2.16 | $2.16 | $1.29 | $2.12 | $2.33 | $1.98 | $0.64 | $2.34 | $1.67 | $1.38 | $0.53 | $0.98 | $0.84 | $0.45 | $0.29 | $0.75 | $0.61 | $5.39 | $0.13 | $2.17 | $0.37 |
| High Forecast | $5.79 | $5.20 | $4.81 | $3.39 | $3.24 | $2.95 | $2.12 | $1.78 | $2.08 | $2.52 | $2.38 | $1.42 | $3.25 | $2.90 | $2.18 | $0.71 | $2.57 | $1.84 | $1.38 | $0.59 | $1.09 | $0.94 | $0.51 | $0.32 | $0.83 | $0.68 | $6.02 | $0.14 | $2.42 | $0.42 |
| Low Forecast | $4.72 | $4.24 | $3.92 | $2.76 | $2.64 | $2.41 | $1.73 | $1.45 | $1.70 | $1.80 | $1.94 | $1.16 | $1.31 | $2.06 | $1.78 | $0.58 | $2.10 | $1.50 | $1.38 | $0.49 | $0.90 | $0.77 | $0.42 | $0.27 | $0.68 | $0.56 | $4.95 | $0.12 | $1.99 | $0.34 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.38% | 2.37% | 2.09% | 1.33% | 1.11% | 1.62% | 1.03% | 5.76% | 1.20% | 1.34% | 0.96% | 3.23% | 1.06% | 2.25% |
According to 6 Wall Street analysts, Genmab's projected average Quarter EPS for Jun 23 is $1.98, with a low estimate of $1.78 and a high estimate of $2.18. This represents a 465.40% increase compared to GMAB previous annual EPS of $0.35 (Mar 23).
Genmab Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| TVTX | Travere Therapeutics | $10.98 | $19.50 | 77.60% | Buy |
| AKRO | Akero Therapeutics | $26.41 | $43.50 | 64.71% | Buy |
| LEGN | Legend Biotech | $48.29 | $78.78 | 63.14% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| GMAB | Genmab | $27.52 | $43.00 | 56.25% | Buy |
| CYTK | Cytokinetics | $54.09 | $80.92 | 49.60% | Buy |
| ASND | Ascendis Pharma | $119.15 | $175.15 | 47.00% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| BGNE | BeiGene | $191.32 | $247.75 | 29.50% | Buy |
| BPMC | Blueprint Medicines | $86.43 | $101.50 | 17.44% | Buy |
| PCVX | Vaxcyte | $111.58 | $117.00 | 4.86% | Buy |
GMAB Forecast FAQ
Is Genmab a good buy?
Yes, according to 9 Wall Street analysts, Genmab (GMAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 66.67% of GMAB's total ratings.
What is GMAB's price target?
Genmab (GMAB) average price target is $43 with a range of $31 to $53, implying a 56.25% from its last price of $27.52. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Genmab stock go up soon?
According to Wall Street analysts' prediction for GMAB stock, the company can go up by 56.25% (from the last price of $27.52 to the average price target of $43), up by 92.59% based on the highest stock price target, and up by 12.65% based on the lowest stock price target.
Can Genmab stock reach $40?
GMAB's average twelve months analyst stock price target of $43 supports the claim that Genmab can reach $40 in the near future.
What is Genmab's current price target trend?
2 Wall Street analysts forecast a $38.5 price target for Genmab (GMAB) this month, up 39.90% from its last price of $27.52. Compared to the last 3 and 12 months, the average price target increased by 58.07% and increased by 66.53%, respectively.
What are Genmab's analysts' financial forecasts?
Genmab's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $24.5B (high $26.41B, low $22.58B), average EBITDA is $11.96B (high $12.9B, low $11.03B), average net income is $594.1M (high $654.56M, low $533.67M), average SG&A $3.21B (high $3.46B, low $2.96B), and average EPS is $9.16 (high $10.09, low $8.22). GMAB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $30.83B (high $33.25B, low $28.42B), average EBITDA is $15.06B (high $16.24B, low $13.88B), average net income is $1.13B (high $1.24B, low $1.01B), average SG&A $4.04B (high $4.36B, low $3.73B), and average EPS is $17.41 (high $19.19, low $15.64).
Did the GMAB's actual financial results beat the analysts' financial forecasts?
Based on Genmab's last annual report (Dec 2022), the company's revenue was $14.6B, beating the average analysts forecast of $11.55B by 26.40%. Apple's EBITDA was $7.04B, beating the average prediction of $5.64B by 24.90%. The company's net income was $5.52B, beating the average estimation of $5.36B by 3.08%. Apple's SG&A was $2.68B, beating the average forecast of $2.53B by 5.77%. Lastly, the company's EPS was $8.45, beating the average prediction of $5.92 by 42.75%. In terms of the last quarterly report (Mar 2023), Genmab's revenue was $2.85B, beating the average analysts' forecast of $2.77B by 3.06%. The company's EBITDA was $629M, missing the average prediction of $1.35B by -53.49%. Genmab's net income was $226M, missing the average estimation of $5.93B by -96.19%. The company's SG&A was $676M, beating the average forecast of $363.24M by 86.10%. Lastly, the company's EPS was $0.35, missing the average prediction of $0.642 by -45.50%